BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
Aug 19, 2026
VANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...



